Pharmaceutical

Low molecular weight heparin drug found effective in IVF-ET

Enoxaparin, a low-molecular weight heparin, is getting praise from the Journal of Human Fertility for its safety and effectiveness for the prophylactic treatment of women with thrombophilia and recurrent in vitro fertilization-embryo transfer (IVF-ET) failures, according to IVG News.Direct!

Thrombophilia refers to a number of genetic conditions that increase the tendency of the blood to clot, which can lead to serious and/or life-threatening complications depending on the location of the clot. It is a major factor associated with recurrent IVF-ET, as it can cause complications in pregnancy such as stillbirth, preeclampsia and declampsia.

The study included 83 women with a history of three or more previous IVF failures who had at least one thrombophilic defect. One group received 40 mg of enoxaparin per day, the other received a placebo. Both treatments were started on the day of embryo transfer (ET) and continued until delivery or until feotal demise.

According to the study, patients who received the low-molecular weight heparin had a significant increase in the implantation and pregnancy rates compared to those who took the placebo: Those on enoxaparin had a 20.9 percent implantation rate and a 31 percent pregnancy rate as opposed to the placebo group which had a 6.1 implantation rate and a 9.6 pregnancy rate. There also was a significant increase in the live birth rate – 23.8 percent in the group taking enoxaparin to 2.8 percent in the placebo group.